Next generation anti-CTLA-4 inhibitors demonstrate improved antitumour activity with reduced toxicity.
Next generation anti-CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumour-restricted activation. The goal is to achieve robust antitumour activity without inducing systemic immune-related toxicity.
No takes yet. Share an insight, caveat, or question.
Galvez-Cancino et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: